Table 3.
Predictors of attendance to the general population cervical cancer screening program in WLWH 1 aged 30, 40 and 50 years
| Predictors of attendance in different age groups | 30 years (n = 379) | 40 years (n = 563) | 50 years (n = 218) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| |
n (%) attending screening |
Unadjusted |
Adjusted |
n (%) attending screening |
Unadjusted |
Adjusted |
n (%) attending screening |
Unadjusted |
Adjusted |
| Mode of transmission, | |||||||||
| Heterosexual contact |
197 (70.1) |
1.00‡ |
1.00‡ |
315 (78.6) |
1.00† |
1.00‡ |
132 (89.2) |
1.00‡ |
1.00‡ |
| Intravenous drug use |
15 (60.0) |
0.64 (0.28-1.48) |
0.53 (0.21-1.35) |
36 (63.2) |
0.47 (0.26-0.84) |
0.70 (0.35-1.38) |
23 (82.1) |
0.56 (0.19-1.67) |
0.74 (0.22-2.46) |
| Other |
4 (57.1) |
0.57 (0.13-2.60) |
0.42 (0.09-2.02) |
8 (66.7) |
0.55 (0.16-1.86) |
0.37 (0.11-1.32) |
3 (100) |
-2 |
-2 |
| (missing) |
(66) |
|
|
(93) |
|
|
(0) |
|
|
| Race, | |||||||||
| White |
76 (71.0) |
1.00‡ |
1.00‡ |
154 (73.7) |
1.00‡ |
1.00‡ |
89 (84.8) |
1.00‡ |
1.00‡ |
| Asian |
36 (62.1) |
0.67 (0.34-1.31) |
0.45 (0.21-0.98) |
42 (80.8) |
1.50 (0.71-3.19) |
1.14 (0.51-2.60) |
12 (92.3) |
2.16 (0.26-17.76) |
1.66 (0.19-14.77) |
| Black |
106 (68.8) |
0.90 (0.53-1.54) |
0.72 (0.38-1.34) |
170 (79.8) |
1.41 (0.90-2.23) |
1.29 (0.77-2.18) |
56 (93.3) |
2.52 (0.80-7.91) |
1.81 (0.52-6.26) |
| Other |
6 (85.7) |
2.45 (0.28-21.17) |
1.98 (0.22-17.68) |
11 (68.8) |
0.79 (0.26-2.36) |
1.14 (0.32-4.11) |
6 (100) |
-1 |
-2 |
| (missing) |
(53) |
|
|
(73) |
|
|
(34) |
|
|
| Calendar period | |||||||||
| 01.01.2002 – 31.12.20023 |
65 (51.2) |
1.00† |
1.00† |
48 (46.6) |
1.00† |
1.00† |
8 (72.7) |
1.00‡ |
1.00‡ |
| 01.01.2003 – 31.12.2010 |
163 (64.7) |
1.75 (1.13-2.69) |
1.77 (1.04-3.02) |
329 (71.5) |
2.88 (1.86-4.45) |
3.45 (2.05-5.78) |
156 (75.4) |
1.15 (0.29-4.49) |
1.04 (0.12-9.33) |
| Time-updated HIV RNA (copies/mL) | |||||||||
| > 500 |
86 (52.8) |
1.00† |
1.00‡ |
90 (54.2) |
1.00† |
1.00† |
29 (60.4) |
1.00† |
1.00‡ |
| < 500 |
137 (66.8) |
1.80 (1.18-2.75) |
1.37 (0.83-2.28) |
279 (73.0) |
2.29 (1.57-3.34) |
1.76 (1.08-2.88) |
130 (79.8) |
2.58 (1.29-5.16) |
2.43 (0.88-6.71) |
| (missing) |
(11) |
|
|
(15) |
|
|
(7) |
|
|
| Time-updated CD4 count (cells/μL) | |||||||||
| < 200 |
33 (56.9) |
1.00‡ |
1.00‡ |
40 (56.3) |
1.00† |
1.00‡ |
14 (58.3) |
1.00‡ |
1.00‡ |
| 200–350 |
42 (52.5) |
0.84 (0.42-1.65) |
0.49 (0.21-1.13) |
61 (58.7) |
1.10 (0.60-2.02) |
0.67 (0.30-1.51) |
24 (70.6) |
1.71 (0.57-5.13) |
1.54 (0.36-6.53) |
| > 350 |
147 (63.9) |
1.34 (0.75-2.41) |
0.76 (0.36-1.61) |
269 (71.9) |
2.00 (1.18-3.34) |
1.07 (0.52-2.19) |
121 (79.1) |
2.70 (1.10-6.64) |
4.33 (1.24-15.10) |
| (missing) | (11) | (14) | (7) | ||||||
Unadjusted and adjusted odds ratios (OR’s) for predictors of attendance. Predictors of attendance to the general population cervical screening program in different age groups were estimated including the month observed closest to 30, 40 and 50 years (+/- 3 years) to determine whether or not the woman was covered by screening. Two models are shown in the table: Mode of transmission, ethnicity and calendar period were included in both models, whereas time-updated HIV RNA was included in the first model and replaced by CD4 count in the second model. We only presented the OR of the CD4 count from the second model, 1Women living with HIV (WLWH), 2Could not be estimated, due to shortage of events, 3Since no data was available before 1999 the reference period only included 2002 to allow for three years observation before initiation.
†The simultaneous test was significant. ‡The simultaneous test was insignificant.